Recruiting
Phase 1
Phase 2

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Sponsor:

DualityBio Inc.

Code:

NCT05150691

Conditions

HER2-positive Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

DB-1303/BNT323

Pertuzumab Injection

Ritonavir

Itraconazole

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information